<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Physiology and Pharmacology</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AF0AF832-B6C2-42F7-B43A-71569B3C4B0C"><gtr:id>AF0AF832-B6C2-42F7-B43A-71569B3C4B0C</gtr:id><gtr:firstName>Zafar</gtr:firstName><gtr:otherNames>Iqbal</gtr:otherNames><gtr:surname>Bashir</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2568C516-386D-4754-8C1A-75D3535FCA0E"><gtr:id>2568C516-386D-4754-8C1A-75D3535FCA0E</gtr:id><gtr:firstName>David.</gtr:firstName><gtr:surname>Lodge</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BF47D388-B1EE-4B33-810A-0EA666A7BC05"><gtr:id>BF47D388-B1EE-4B33-810A-0EA666A7BC05</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:otherNames>Leon</gtr:otherNames><gtr:surname>Collingridge</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C4B4329E-A731-4BC2-8CFC-7311340846E0"><gtr:id>C4B4329E-A731-4BC2-8CFC-7311340846E0</gtr:id><gtr:firstName>Elek</gtr:firstName><gtr:surname>Molnar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/54913D9C-BD57-4B12-814F-358CAFD24B9F"><gtr:id>54913D9C-BD57-4B12-814F-358CAFD24B9F</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Edward</gtr:otherNames><gtr:surname>Jane</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8464CB93-4656-4173-A343-F91F40FA7F7D"><gtr:id>8464CB93-4656-4173-A343-F91F40FA7F7D</gtr:id><gtr:firstName>Zuner</gtr:firstName><gtr:otherNames>Assis</gtr:otherNames><gtr:surname>Bortolotto</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0601812"><gtr:id>8819E087-8F4D-41D1-BEF7-8BB0D132854D</gtr:id><gtr:title>Discovering novel subtype-selective glutamate receptor antagonists for the study of hippocampal synaptic plasticity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601812</gtr:grantReference><gtr:abstractText>The main aim of this work is to design and synthesize new chemical substances to be used as tools to investigate the fundamental mechanism of learning and memory. This research may lead to new treatments for disorders that involve cognitive dysfunction, such as schizophrenia, Alzheimer?s and Parkinson?s disease. 
Communication between one nerve cell (neuron) and others in the brain is effected at the junctions (synapses). One of the main mechanisms by which one cell in a neuronal chain communicates with the next cell is by releasing an amino acid, glutamate from its multiple synaptic endings. We have helped establish that glutamate can interact with a family of structurally related proteins known as glutamate receptor subtypes each performing different functions in the central nervous system (CNS). 
Whereas glutamate activates all the subtypes of glutamate receptor, we aim to produce tools that block the activation of only one subtype of receptor. By observing what effect specific activation or blockade of a particular glutamate receptor subtype has on the functioning of the CNS, one can deduce the particular role of that receptor subtype in the integrated pattern of nervous activity that underlies learning and memory.</gtr:abstractText><gtr:technicalSummary>NMDA receptors (NMDARs) are ligand gated ion channels that belong to the glutamate receptor (GluR) family and are expressed throughout the central nervous system (CNS). NMDARS are tetrameric assemblies of NR1, NR2A-D and NR3A and NR3B subunits. NMDARs have been identified as key players in synaptic plasticity and CNS disorders. However, the roles the different NMDAR subunits play in synaptic plasticity in the hippocampus are poorly understood. A related family of GluRs, the metabotropic glutamate receptors (mGluRs), play a modulatory role in CNS function. Of particular interest are subtypes of group III mGluRs (mGluR7 and 8) as these are known to be expressed in the hippocampus and play a role in synaptic plasticity in this brain region. However, the lack of pharmacological tools that are capable of distinguishing between the various types of NMDAR subunits or the subtypes of mGluRs is hampering our understanding of the functions of NMDARs and mGluRs in synaptic plasticity in the hippocampus. We plan to develop antagonists that are selective for mGluR7, mGluR8, NR2A, NR2B and NR3A. Two interrelated approaches will be adopted to develop isoform specific antagonists, 1) rational drug design based on known structure-activity data combined with the use of X-ray crystal structures and homology models to target unique amino acid residues in the binding site of the protein of interest and 2) validation of hypotheses generated in modelling studies by testing compounds on appropriate point mutations of the protein target. Once mGluR7 and mGluR8 selective antagonists have been identified, we will use them, in conjunction with knockout mice, to elucidate the roles of mGluR7 and mGluR8 in hippocampal synaptic plasticity. The roles of NR2A and NR2B in long-term potentiation (LTP) and long-term depression (LTD) are controversial, largely due to the lack of suitably selective pharmacological tools. The NR2A and NR2B selective antagonists developed here will be used to probe the roles of these subunits in hippocampal synaptic function. Very little is known about the functions of NR3 subunits in LTP and LTD. We will therefore use selective antagonists to investigate plasticity at CA3-CA1 synapses where the NR3 subunit is expressed in young animals. We also plan to develop biotin-conjugated photoaffinity ligands and fluorescently labelled compounds based on the isoform specific antagonists identified during this project. These will be used to investigate the molecular organisation, developmental regulation, regional, cellular and subcellular distribution and trafficking of the native NMDARs and mGluRs.</gtr:technicalSummary><gtr:fund><gtr:end>2012-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1852233</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eli Lilly &amp; Company Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Discovery of novel NR2A/NR2B selective antagonists</gtr:description><gtr:id>5C938C27-2FAE-4394-8FF1-7F2B65B2311C</gtr:id><gtr:impact>As part of a multidisciplinary project involving chemistry, pharmacology and neuroscience, Eli Lilly have contributred a postdoctoral chemist to work for 3 years on the synthesis of NR2A/NR2B selective antagonists. This will complement the synthetic effort at Bristol. Eli Lilly have funded a researcher for 50% of the time to test compounds synthesised at Lilly and will also pay for running costs for the pharmacological screening. As mentioned elsewhere Eli Lilly have appointed a postdoctoral chemist to work at their site at Erl Wood, Surrey, engaged on the synthesis of NR2A/NR2B antagonists to support the synthetic chemistry effort at Bristol. Once selective antagonists have been identified they will be fed into projects in the MRC centre of Synaptic Plasticity. I am also part of the Centre for Cognitive Neuroscience (CCN) set up by Eli Lilly and compounds generated as a result of our collaboration will also be fed into projects within the CCN.</gtr:impact><gtr:partnerContribution>Eli Lilly have appointed a postdoctoral chemist to work at their site at Erl Wood, Surrey, engaged on the synthesis of NR2A/NR2B antagonists to support the synthetic chemistry effort at Bristol. Once selective antagonists have been identified they will be fed into projects in the MRC centre of Synaptic Plasticity. I am also part of the Centre for Cognitive Neuroscience (CCN) set up by Eli Lilly and compounds generated as a result of our collaboration will also be fed into projects within the CCN.</gtr:partnerContribution><gtr:piContribution>I have provided medicinal chemsitry expertise to develop targets for NR2A and NR2B antagonists. I have also co-supervised the postdoctoral chemsit at Eli Lilly. I participate in twice yearly meetings of the CCN at Eli Lilly. A postdoc is funded 50% of time to test compounds on NMDA receptor subtypes.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>lecture and interactive tutorial</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B1970BD9-F2D9-4C14-9312-8A5372323A14</gtr:id><gtr:impact>Gave a lecture and interactive computer-based tutorial entitled &amp;quot;drugs as molecules&amp;quot; for local school children. The lecture included an explanation of my research activities and their possible implications for the treatment of neurological disorders.

Impact of visit not assessed</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International conference on glutamate receptors</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C179A532-EE0A-406E-BF14-C187AC1E3744</gtr:id><gtr:impact>Talked sparked lively discussion and opened up the possibility of new collaborations with scientists in the audience.

No notable impacts</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://conferences-on-aminoacidergic-transmission.eu/index.php/conference-2014</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C511AB43-EA29-415C-A5EE-77711555D879</gtr:id><gtr:impact>Two school pupils per year visited my laboratory and shadowed research workers in my laboratory to gain an insight into the research carried out in my group. This included interactive demonstrations of computer-aided drug design, how drugs are synthesised by chemists, how they are evaluated pharmacologically and then tested in a model of synaptic plasticity.

The pupils gave the visit a high rating and are now thinking of choosing a science based subject to study at university.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>637120</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant, Responsive Mode. Identifying role of NMDA receptors in STP</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/L001977/1</gtr:fundingRef><gtr:id>B22CDC9C-4FE8-4EA6-8700-983BD6379FD4</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>638364</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant, Responsive Mode. Development of biotin-tagged affinity ligands and fluorophore-conjugated probes for the study of native kainate receptors</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/J015938/1</gtr:fundingRef><gtr:id>556FB18D-2632-4298-83E4-4EB9FB2691AE</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>694</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Elucidation of the role of kainate receptor subtypes in hippocampal synaptic function using novel pharmacological tools</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/F012519/1</gtr:fundingRef><gtr:id>59FC77C5-CA92-4103-9573-CC4AE9886BD8</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2008-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1821280</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:department>National Institute of Mental Health (NIMH)</gtr:department><gtr:description>Project grant. Development and pharmacology of positive allosteric modulators of NMDA receptiors</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>2R01MH060252-09A1</gtr:fundingRef><gtr:id>95CF614F-BAA2-4043-B1E2-7ACAC847259B</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>UBP161 is an antagonist that is selective for GluK1 in the kainate receptor family but also has antagonist activity at NMDA receptors.</gtr:description><gtr:id>8CCE4F1B-DD00-4174-ACF8-746463F424D3</gtr:id><gtr:impact>We have recently reported that UBP161 showed antinociceptive effects in an animal model of mild nerve injury.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UBP161, a dual antagonist of GluK1 and NMDA receptors</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>new radiolabelled form of UBP310 a selective GluK1/GluK3 kainate receptor antagonist</gtr:description><gtr:id>9D8DBD0D-5A81-4CB9-8AFD-8F43CE363A49</gtr:id><gtr:impact>Paper published in Molecular Pharmacology</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>[3H]UBP310 new radioligand for GluK1 kainate receptors</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Negative allosteric modulator of the NMDA receptor</gtr:description><gtr:id>478D3ABF-B425-4744-BB53-0C1B84FEB15D</gtr:id><gtr:impact>Resulted in a publication in Neurochemistry International.
Now sold by the neurochemical company Sigma Aldrich.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UBP608</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.sigmaaldrich.com/catalog/product/sigma/sml0606?lang=en&amp;region=GB</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>An mGlu8 receptor selective antagonist</gtr:description><gtr:id>2609FE2D-7528-41E8-AF23-5EFD11B491D6</gtr:id><gtr:impact>Collaboration with Prof David Lodge and Prof Graham Collingridge resulted in two papers in Neuropharmacology.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MDCPG</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The initial work leading to the development of a range of selective GluK1 (GluR5) kainate receptor antagonists such as UBP282, UBP296, UBP302, UBP304, UBP310 and ACET was funded by an MRC programme grant.</gtr:description><gtr:id>78507A49-BA6B-4EC6-9928-2E242B38E462</gtr:id><gtr:impact>Allowed some of the physiological roles of GluK1 (GluR5) containing kainate receptors to be identified including their role in hippocampal synaptic mechanisms and object recognition memory. Led to a collaboration with Eli Lilly and company on the development of kainate receptor antagonists and a consultancy position being set up with the company to advise on the development of KAR antagonists for clinical applications such as treatment of neuropathic pain and migraine. The initial work funded by the MRC led to further funding by the BBSRC (two 3 year project grants).
Sold by Tocris Bioscience</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ACET a GluK1 receptor antagonist</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.tocris.com/dispprod.php?ItemId=40541#.VFyxgfmsUaw</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have recently identified a range of novel compounds that bind to allosteric sites on the NMDA receptor. Some are positive allosteric modulators that interact seelctively with particular GluN2 subtypes. We have also identified negative allosteric modulators that interact selectively with GluN2C/GluN2D subunits</gtr:description><gtr:id>1010E7B8-15A0-4528-AA7A-42469BEF8378</gtr:id><gtr:impact>The new compounds have only recently been identified but given their mode of action and subtype selectivity they are likely to have a large impact on the glutamate receptor field and we have already had interest from a number of drug companies. We have published a paper in JPET.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Subtype selective positive and negative allosteric modulators of NMDA receptors</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Positive allosteric modulator of the NMDA receptor</gtr:description><gtr:id>6238521F-74F1-4C6E-BEB9-C61C948EFA0F</gtr:id><gtr:impact>Resulted in a publication in Neurochemistry International.
UBP714 is now sold by the neurochemical company Sigma Aldrich</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UBP714</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.sigmaaldrich.com/catalog/product/sigma/sml0718?lang=en&amp;region=GB</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C720BA6-2F8A-48A5-99D9-B8B12543A32E"><gtr:id>8C720BA6-2F8A-48A5-99D9-B8B12543A32E</gtr:id><gtr:title>Pre- and post-synaptic functions of kainate receptors at glutamate and GABA synapses in the rat entorhinal cortex.</gtr:title><gtr:parentPublicationTitle>Hippocampus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1221422b564b9a650163364dd9ac9638"><gtr:id>1221422b564b9a650163364dd9ac9638</gtr:id><gtr:otherNames>Chamberlain SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1050-9631</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FF18575D-122B-4F63-9515-959075B27227"><gtr:id>FF18575D-122B-4F63-9515-959075B27227</gtr:id><gtr:title>Extrasynaptic NR2D-containing NMDARs are recruited to the synapse during LTP of NMDAR-EPSCs.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/154003f09127696b40f3eb4f59ac6780"><gtr:id>154003f09127696b40f3eb4f59ac6780</gtr:id><gtr:otherNames>Harney SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/23A66EC6-BE53-4A9C-95B4-ACCE8AA38DCF"><gtr:id>23A66EC6-BE53-4A9C-95B4-ACCE8AA38DCF</gtr:id><gtr:title>Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [3H]UBP310.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fca51e4a642a6cee4284c20665681156"><gtr:id>fca51e4a642a6cee4284c20665681156</gtr:id><gtr:otherNames>Atlason PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F7048150-9AE3-44AB-9C4C-F0FAA4802CC5"><gtr:id>F7048150-9AE3-44AB-9C4C-F0FAA4802CC5</gtr:id><gtr:title>Metabotropic glutamate receptor mGlu2 is resistant to homologous agonist-induced desensitization but undergoes protein kinase C-mediated heterologous desensitization.</gtr:title><gtr:parentPublicationTitle>European journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44dc1ca33fee1a868dc64d700ccca41d"><gtr:id>44dc1ca33fee1a868dc64d700ccca41d</gtr:id><gtr:otherNames>Lennon SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-2999</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/489E72EA-80B7-485A-A5E9-BE1C8BF7870D"><gtr:id>489E72EA-80B7-485A-A5E9-BE1C8BF7870D</gtr:id><gtr:title>Dynamin-dependent membrane drift recruits AMPA receptors to dendritic spines.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07a5a620c056a9353f5d876c5d5e8be5"><gtr:id>07a5a620c056a9353f5d876c5d5e8be5</gtr:id><gtr:otherNames>Jaskolski F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9AE50316-3932-4299-8044-767AACAC70C8"><gtr:id>9AE50316-3932-4299-8044-767AACAC70C8</gtr:id><gtr:title>Antagonists reversibly reverse chemical LTD induced by group I, group II and group III metabotropic glutamate receptors.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e274d7984dd8e97e192e7bc0ca4a8bb4"><gtr:id>e274d7984dd8e97e192e7bc0ca4a8bb4</gtr:id><gtr:otherNames>Lodge D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/950F5833-F1F2-44A3-A611-0C7C687904C6"><gtr:id>950F5833-F1F2-44A3-A611-0C7C687904C6</gtr:id><gtr:title>Piperazine-2,3-dicarboxylic acid derivatives as dual antagonists of NMDA and GluK1-containing kainate receptors.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eee6c813b49c9029aba5a95664ef9f11"><gtr:id>eee6c813b49c9029aba5a95664ef9f11</gtr:id><gtr:otherNames>Irvine MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/44B6F717-F0EB-4493-AE28-D77096F2FC2C"><gtr:id>44B6F717-F0EB-4493-AE28-D77096F2FC2C</gtr:id><gtr:title>NMDA receptor-dependent long-term potentiation comprises a family of temporally overlapping forms of synaptic plasticity that are induced by different patterns of stimulation.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/504c611074b424abf30d166ff26f65b0"><gtr:id>504c611074b424abf30d166ff26f65b0</gtr:id><gtr:otherNames>Park P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8E59084B-6B82-49C5-AD23-CA857C90B271"><gtr:id>8E59084B-6B82-49C5-AD23-CA857C90B271</gtr:id><gtr:title>N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/517505223e045999181f1b437a1bb49a"><gtr:id>517505223e045999181f1b437a1bb49a</gtr:id><gtr:otherNames>Costa BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E78BBCC2-FB91-4EDD-B7BD-2EF44B29AB5E"><gtr:id>E78BBCC2-FB91-4EDD-B7BD-2EF44B29AB5E</gtr:id><gtr:title>Long-term potentiation and the role of N-methyl-D-aspartate receptors.</gtr:title><gtr:parentPublicationTitle>Brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dd7211f83cdd1dffd0e5884042c0ccd0"><gtr:id>dd7211f83cdd1dffd0e5884042c0ccd0</gtr:id><gtr:otherNames>Volianskis A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8993</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A01C2EFE-A4F8-4B41-ACFC-47F98310FDA1"><gtr:id>A01C2EFE-A4F8-4B41-ACFC-47F98310FDA1</gtr:id><gtr:title>Allosteric block of KCa2 channels by apamin.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7f78024e0e86ff4204dce51e8e4d5ed8"><gtr:id>7f78024e0e86ff4204dce51e8e4d5ed8</gtr:id><gtr:otherNames>Lamy C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A6C5BA6E-65E6-4250-8519-B76D52393D58"><gtr:id>A6C5BA6E-65E6-4250-8519-B76D52393D58</gtr:id><gtr:title>Different NMDA receptor subtypes mediate induction of long-term potentiation and two forms of short-term potentiation at CA1 synapses in rat hippocampus in vitro.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dd7211f83cdd1dffd0e5884042c0ccd0"><gtr:id>dd7211f83cdd1dffd0e5884042c0ccd0</gtr:id><gtr:otherNames>Volianskis A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FF46F7D9-BC8B-4ADB-87C5-B2BA7961AF9A"><gtr:id>FF46F7D9-BC8B-4ADB-87C5-B2BA7961AF9A</gtr:id><gtr:title>Selective inhibition of GluN2D-containing N-methyl-D-aspartate receptors prevents tissue plasminogen activator-promoted neurotoxicity both in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Molecular neurodegeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42aae7b4c1f1f58c6d1661238f06a841"><gtr:id>42aae7b4c1f1f58c6d1661238f06a841</gtr:id><gtr:otherNames>Jullienne A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1750-1326</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A0C823DC-6A91-480B-86B9-873BF977C4C7"><gtr:id>A0C823DC-6A91-480B-86B9-873BF977C4C7</gtr:id><gtr:title>Multiple roles of GluN2B-containing NMDA receptors in synaptic plasticity in juvenile hippocampus.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b7724d1af47c203e377aff88be600144"><gtr:id>b7724d1af47c203e377aff88be600144</gtr:id><gtr:otherNames>France G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3BEA6953-F437-41A9-B88A-51552C8A8CED"><gtr:id>3BEA6953-F437-41A9-B88A-51552C8A8CED</gtr:id><gtr:title>Functional heterogeneity of NMDA receptors in rat substantia nigra pars compacta and reticulata neurones.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/18a93a1e19bdcc28e89332ceabdd4f2a"><gtr:id>18a93a1e19bdcc28e89332ceabdd4f2a</gtr:id><gtr:otherNames>Su?rez F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CF643812-693D-4B6E-A860-D3C3D8F892ED"><gtr:id>CF643812-693D-4B6E-A860-D3C3D8F892ED</gtr:id><gtr:title>NR2B- and NR2D-containing synaptic NMDA receptors in developing rat substantia nigra pars compacta dopaminergic neurones.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b4e2542fbf876114051f1d7d785b47f"><gtr:id>6b4e2542fbf876114051f1d7d785b47f</gtr:id><gtr:otherNames>Brothwell SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/67412920-78EE-418F-8CD4-A9E4DB8E933C"><gtr:id>67412920-78EE-418F-8CD4-A9E4DB8E933C</gtr:id><gtr:title>Synthesis of a Series of Novel 3,9-Disubstituted Phenanthrenes as Analogues of Known NMDA Receptor Allosteric Modulators.</gtr:title><gtr:parentPublicationTitle>Synthesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eee6c813b49c9029aba5a95664ef9f11"><gtr:id>eee6c813b49c9029aba5a95664ef9f11</gtr:id><gtr:otherNames>Irvine MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0039-7881</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EE8A1774-AA25-4ED8-A7AA-16335BFBCD96"><gtr:id>EE8A1774-AA25-4ED8-A7AA-16335BFBCD96</gtr:id><gtr:title>Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.</gtr:title><gtr:parentPublicationTitle>Neurochemistry international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9ab7ac8bdd7c01446cfafba20647da95"><gtr:id>9ab7ac8bdd7c01446cfafba20647da95</gtr:id><gtr:otherNames>Monaghan DT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-0186</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/709A7B6E-5F7D-4868-B9AA-D488E0785A77"><gtr:id>709A7B6E-5F7D-4868-B9AA-D488E0785A77</gtr:id><gtr:title>An interchangeable role for kainate and metabotropic glutamate receptors in the induction of rat hippocampal mossy fiber long-term potentiation in vivo.</gtr:title><gtr:parentPublicationTitle>Hippocampus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bedc9a492043cea84e6502b694ee9bbc"><gtr:id>bedc9a492043cea84e6502b694ee9bbc</gtr:id><gtr:otherNames>Wallis JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1050-9631</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4B5C88B0-64ED-46B2-ADC4-0E157F74FF71"><gtr:id>4B5C88B0-64ED-46B2-ADC4-0E157F74FF71</gtr:id><gtr:title>Textbook of Drug Design and Development</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4bc718de75b3cdf257759c1c387f3d28"><gtr:id>4bc718de75b3cdf257759c1c387f3d28</gtr:id><gtr:otherNames>Jane DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:isbn>9781420063226</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B30B938D-C4A5-406C-B054-E9FE62D44E45"><gtr:id>B30B938D-C4A5-406C-B054-E9FE62D44E45</gtr:id><gtr:title>Neuronal calcium sensors and synaptic plasticity.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f4667334179bfe3f882512c138644546"><gtr:id>f4667334179bfe3f882512c138644546</gtr:id><gtr:otherNames>Amici M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6F6FF485-9252-4177-B744-30101C7BCC49"><gtr:id>6F6FF485-9252-4177-B744-30101C7BCC49</gtr:id><gtr:title>Mechanisms of antagonism of the GluR2 AMPA receptor: structure and dynamics of the complex of two willardiine antagonists with the glutamate binding domain.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eec462f65f1a6877171691b776e2021e"><gtr:id>eec462f65f1a6877171691b776e2021e</gtr:id><gtr:otherNames>Ahmed AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CE5B85C9-D195-4928-B5E1-68D324BBABAF"><gtr:id>CE5B85C9-D195-4928-B5E1-68D324BBABAF</gtr:id><gtr:title>The NMDA receptor as a target for cognitive enhancement.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8606ab1418d621c0ce28e517cb05f051"><gtr:id>8606ab1418d621c0ce28e517cb05f051</gtr:id><gtr:otherNames>Collingridge GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4A2DFCC2-38C8-4941-858F-D73087402B92"><gtr:id>4A2DFCC2-38C8-4941-858F-D73087402B92</gtr:id><gtr:title>Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/517505223e045999181f1b437a1bb49a"><gtr:id>517505223e045999181f1b437a1bb49a</gtr:id><gtr:otherNames>Costa BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6ECB54A8-8443-4C90-BDB2-24AA33ED9046"><gtr:id>6ECB54A8-8443-4C90-BDB2-24AA33ED9046</gtr:id><gtr:title>Ca2+-calmodulin increases RyR2 open probability yet reduces ryanoid association with RyR2.</gtr:title><gtr:parentPublicationTitle>Biophysical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ae0e6376447a3120bd99615ed58c2cb7"><gtr:id>ae0e6376447a3120bd99615ed58c2cb7</gtr:id><gtr:otherNames>Sigalas C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3495</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7DB4D561-9F55-4477-9FCF-A94EA7BF2406"><gtr:id>7DB4D561-9F55-4477-9FCF-A94EA7BF2406</gtr:id><gtr:title>Small conductance calcium-activated potassium channels: from structure to function.</gtr:title><gtr:parentPublicationTitle>Progress in neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/107e4bdb86645d23cd242befd85d8f1d"><gtr:id>107e4bdb86645d23cd242befd85d8f1d</gtr:id><gtr:otherNames>Weatherall KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0301-0082</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3DC23EF5-4CEA-4366-BBDD-29757236E727"><gtr:id>3DC23EF5-4CEA-4366-BBDD-29757236E727</gtr:id><gtr:title>Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-D-aspartate receptors.</gtr:title><gtr:parentPublicationTitle>Neurochemistry international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eee6c813b49c9029aba5a95664ef9f11"><gtr:id>eee6c813b49c9029aba5a95664ef9f11</gtr:id><gtr:otherNames>Irvine MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-0186</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/76E1E490-4B50-4257-9DD9-F75A3268B338"><gtr:id>76E1E490-4B50-4257-9DD9-F75A3268B338</gtr:id><gtr:title>Characterisation of an mGlu8 receptor-selective agonist and antagonist in the lateral and medial perforant path inputs to the dentate gyrus.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/18929f373fcf137e5fc0b9cecddd66ce"><gtr:id>18929f373fcf137e5fc0b9cecddd66ce</gtr:id><gtr:otherNames>Mercier MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8771CD98-B82F-4D74-9A17-99B472C6E03A"><gtr:id>8771CD98-B82F-4D74-9A17-99B472C6E03A</gtr:id><gtr:title>Differences in kainate receptor involvement in hippocampal mossy fibre long-term potentiation depending on slice orientation.</gtr:title><gtr:parentPublicationTitle>Neurochemistry international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c428740be3ba107280eee12cae94772"><gtr:id>7c428740be3ba107280eee12cae94772</gtr:id><gtr:otherNames>Sherwood JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-0186</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/988D8A6E-47A8-4A91-8047-73B3CFDCEBC9"><gtr:id>988D8A6E-47A8-4A91-8047-73B3CFDCEBC9</gtr:id><gtr:title>A novel family of negative and positive allosteric modulators of NMDA receptors.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/517505223e045999181f1b437a1bb49a"><gtr:id>517505223e045999181f1b437a1bb49a</gtr:id><gtr:otherNames>Costa BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601812</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1A41A859-2076-46E6-B80F-CE4E1E8EDC1D</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>1.5  Resources and infrastructure (underpinning)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>